Evotec: Insider Disposal and Voting Rights Reshuffle Add to Turnover Story

Evotec updates voting rights to 177.9M shares; stock down 23.6% YoY. Insider sale by Dr. Dohrmann and Nasdaq delisting add to transition narrative amid analyst divergence.

Evotec has updated its voting rights tally to 177,907,695 following the issuance of subscription shares, a routine corporate housekeeping step that nonetheless highlights the structural changes under way at the Hamburg-based drug discovery specialist. The move translates into a market capitalisation of roughly €908 million based on Friday’s closing price of €5.24, where the stock gained 3.15% on the day.

That tentative bounce, however, masks a share price that has spent the better part of a year in retreat. After plumbing a 52-week low of €4.14 in March, Evotec has clawed back above its 50-day moving average of €4.91 but remains firmly below the 200-day line at €5.65 – a gap of 7.4%. Over the trailing twelve months the stock has shed 23.6%, though one technical assessment puts the decline at 25.96% and notes an annualised monthly volatility of 46.58%. The relative strength index of 59.7 points to neither oversold nor overbought territory.

That technical indecision mirrors the operational picture. Evotec’s first-quarter numbers showed group revenue of €156.6 million and an adjusted EBITDA loss of €21.9 million, swinging from a profit of €3.1 million a year earlier. The comparison is distorted by the prior period’s inclusion of a Sandoz licence sale, but the underlying trend is clear: the company’s “Horizon” transformation programme is weighing on near-term performance as it rejigs cost structures, growth profiles and value chains. Cash and equivalents stood at €444.8 million at quarter-end, down from €476.4 million at the start of the year – a modest burn that nevertheless underscores the need for the restructuring to deliver tangible margin improvement.

Amid this backdrop, a director transaction caught the market’s eye. Dr. Cord Dohrmann sold shares on 20 May 2026, a disposal linked to employee or shareholder programme exercises that was publicly disclosed two days later. Such moves are often mechanical – tied to option vesting or tax obligations – but in a stock still viewed as high-risk, any insider sale amplifies attention. The share price showed no immediate negative reaction, yet the episode adds to the narrative of a company in transition.

Another layer of complexity came with Evotec’s decision to delist its American Depositary Shares from the Nasdaq Global Select Market. Management cited lower complexity and listing costs, aiming to concentrate liquidity on the Frankfurt main board. For US-based investors, the shift means direct access now requires European exchanges or over-the-counter instruments – a frictional change that could temper international visibility even if it doesn’t affect operations.

Analyst opinion remains deeply split. RBC Capital Markets rates the stock “Outperform” with a target of €10.00, echoing Berenberg’s buy call. The Deutsche Bank, by contrast, takes a “Hold” stance with a €4.50 target, cautious on the pace of recovery. That divergence captures the uncertainty around Evotec’s pipeline monetisation and cash-flow trajectory following its €116.1 million convertible bond placement.

Shareholders will get a chance to press for clarity at the annual general meeting scheduled for 11 June in Hamburg. Among the agenda items is the election of Dieter Weinand as chairman of the supervisory board. More importantly, the meeting is expected to shed light on the strategic direction of Evotec’s drug discovery pipeline and the financial planning underpinning the Horizon overhaul. Until then, the stock remains caught between a technical repair job and a fundamental restructuring that has yet to show clear results.